Traders Buy Large Volume of Call Options on Cabaletta Bio (NASDAQ:CABA)

Cabaletta Bio, Inc. (NASDAQ:CABA) was the target of unusually large options trading on Thursday. Traders bought 3,428 call options on the company. This represents an increase of 83% compared to the typical volume of 1,871 call options.

Insider Transactions at Cabaletta Bio

In other news, Director Mark Simon acquired 11,061 shares of Cabaletta Bio stock in a transaction that occurred on Wednesday, January 21st. The shares were purchased at an average cost of $2.28 per share, for a total transaction of $25,219.08. Following the completion of the purchase, the director directly owned 147,205 shares of the company’s stock, valued at $335,627.40. This trade represents a 8.12% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Steven Nichtberger acquired 45,000 shares of the firm’s stock in a transaction on Wednesday, January 21st. The stock was acquired at an average cost of $2.24 per share, with a total value of $100,800.00. Following the acquisition, the chief executive officer owned 1,031,483 shares of the company’s stock, valued at $2,310,521.92. This trade represents a 4.56% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders bought 127,668 shares of company stock valued at $286,211 in the last three months. Corporate insiders own 11.25% of the company’s stock.

Hedge Funds Weigh In On Cabaletta Bio

Hedge funds have recently made changes to their positions in the business. Bain Capital Life Sciences Investors LLC raised its holdings in shares of Cabaletta Bio by 250.5% in the 2nd quarter. Bain Capital Life Sciences Investors LLC now owns 9,677,125 shares of the company’s stock worth $14,709,000 after purchasing an additional 6,916,237 shares in the last quarter. Adage Capital Partners GP L.L.C. increased its holdings in shares of Cabaletta Bio by 142.9% in the second quarter. Adage Capital Partners GP L.L.C. now owns 8,829,758 shares of the company’s stock valued at $13,421,000 after buying an additional 5,195,285 shares in the last quarter. Jennison Associates LLC increased its holdings in shares of Cabaletta Bio by 147.4% in the second quarter. Jennison Associates LLC now owns 6,020,167 shares of the company’s stock valued at $9,151,000 after buying an additional 3,586,439 shares in the last quarter. Jefferies Financial Group Inc. acquired a new stake in shares of Cabaletta Bio during the 2nd quarter valued at $3,036,000. Finally, Woodline Partners LP boosted its stake in shares of Cabaletta Bio by 75.2% during the 3rd quarter. Woodline Partners LP now owns 2,135,348 shares of the company’s stock worth $4,997,000 after acquiring an additional 916,884 shares in the last quarter.

Cabaletta Bio Stock Up 25.6%

CABA stock opened at $2.94 on Friday. The company has a 50-day simple moving average of $2.30 and a 200 day simple moving average of $2.12. The company has a market capitalization of $283.00 million, a P/E ratio of -1.16 and a beta of 3.25. Cabaletta Bio has a fifty-two week low of $0.99 and a fifty-two week high of $3.67.

Cabaletta Bio (NASDAQ:CABA) last released its earnings results on Monday, November 10th. The company reported ($0.44) EPS for the quarter, beating the consensus estimate of ($0.49) by $0.05. Equities analysts anticipate that Cabaletta Bio will post -2.34 EPS for the current year.

Key Stories Impacting Cabaletta Bio

Here are the key news stories impacting Cabaletta Bio this week:

• Positive Sentiment: CEO Steven Nichtberger purchased 45,000 shares at an average ~$2.24, increasing his stake to ~1.03M shares — a sizable insider buy from the company’s top executive. Read More.
• Positive Sentiment: Multiple other insiders (director Mark Simon, director Shawn Tomasello, insiders Steve Gavel, Gwendolyn Binder, David J. Chang, and General Counsel Michael Gerard) executed material purchases at ~$2.19–$2.28 per share — broad insider participation that signals management/board conviction. Read More.
• Positive Sentiment: Unusually large options activity: investors bought ~3,428 CABA call options (an ~83% increase vs. average daily call volume), consistent with short‑term bullish speculative interest.
• Positive Sentiment: Company program update coverage: reports say Cabaletta is accelerating its autoimmune CAAR‑T program and is targeting a 2027 FDA filing — a clear development roadmap that could materially de‑risk value if milestones are met. Read More.
• Neutral Sentiment: Analyst coverage remains skewed positive on the longer term (consensus “Moderate Buy” with an average price target well above current levels), but those price targets reflect successful clinical progress and are not guarantees. Read More.
• Neutral Sentiment: Institutional ownership moves reported previously show larger biotech investors increasing stakes — supportive for liquidity, but not an immediate catalyst.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on CABA. Jefferies Financial Group began coverage on Cabaletta Bio in a research report on Friday, October 10th. They issued a “buy” rating and a $14.00 target price on the stock. Cantor Fitzgerald upped their price target on shares of Cabaletta Bio from $15.00 to $30.00 and gave the stock an “overweight” rating in a research report on Friday, October 31st. HC Wainwright reiterated a “buy” rating and issued a $16.00 price objective on shares of Cabaletta Bio in a research report on Friday, October 10th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Cabaletta Bio in a research note on Wednesday, October 8th. Seven analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Cabaletta Bio has an average rating of “Moderate Buy” and an average target price of $16.25.

About Cabaletta Bio

Cabaletta Bio is a clinical-stage biotechnology company pioneering chimeric autoantibody receptor T cell (CAAR-T) therapies for B cell–mediated autoimmune diseases. Its proprietary platform engineers patient-derived T cells to selectively target and eliminate pathogenic B cells that produce disease-driving autoantibodies, with the aim of preserving overall immune function and reducing off-target toxicity.

The company’s lead candidate, DSG3-CAART, is being evaluated in pemphigus vulgaris, a rare blistering disorder caused by autoantibodies against desmoglein 3.